815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Jacobs entered a $1.5 billion revolving credit facility and two term loan facilities totaling $1.2 billion, all dated March 16, 2026. The company said it will use the borrowings, along with cash on hand if needed, to finance the cash purchase of the remaining shares of PA Consulting Group Limited, and the filing says the new facilities replace the existing revolving credit agreement.
Revolving facility of $1.5 billion matures March 16, 2031; JEGI borrowed $545 million on March 16 to repay the existing revolver, and the company borrowed about $56 million for the PA Consulting acquisition.
Term loans of $700 million (maturing March 16, 2029) and $500 million (maturing March 16, 2031) were borrowed on March 17, 2026.
Both agreements require a Consolidated Leverage Ratio of 3.50:1.00 or less, temporarily rising to 4.00:1.00 after certain material acquisitions closes.
Interest rates are based on SOFR and other reference rates plus a margin tied to the company's debt rating or leverage ratio.
On March 17, 2026, Birchtech Corp. said underwriters partially exercised their option to buy additional shares from its February 27, 2026 public offering. The company sold 600,000 more shares at the $2.40 offering price, bringing the total offering to 6,850,000 shares and gross proceeds to about $16.4 million. The filing is a financing update that increases the number of shares outstanding, and 337,500 option shares remain unexercised.
600,000 additional shares sold on March 17, 2026 at the $2.40 offering price
Additional gross proceeds of approximately $1.4 million
Total offering: 6,850,000 shares and approximately $16.4 million in gross proceeds
Indivior Pharmaceuticals, Inc. issued $500 million of 0.625% convertible senior notes due March 15, 2031, including a $50 million option exercised in full, and used part of the proceeds to prepay and terminate its Note Purchase Agreement dated November 4, 2024. The filing names Indivior Pharmaceuticals, Inc. and ticker INDV, not Supernus, as the request stated; the details here follow the filing. Shareholders face potential dilution of up to 16,202,200 shares on conversion, and the notes add $500 million of senior unsecured debt.
$500 million principal of 0.625% Convertible Senior Notes due March 15, 2031, issued March 17, 2026
Initial conversion price of approximately $41.66 per share, a 35.0% premium over the March 12, 2026 closing price
Up to 16,202,200 common shares may be issued on conversion at the initial maximum conversion rate
Prepaid all outstanding principal, interest and fees under the Note Purchase Agreement; it terminated March 17, 2026
Drugs Made In America Acquisition II Corp. issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office on March 11, 2026, as the first payment toward a contemplated $1,400,000 convertible notes financing. The company intends to use the bridge proceeds for accounting, audit and other expenses related to its business combination, and the rest of the financing remains subject to a definitive agreement not yet signed.
Bridge note: $150,000 principal, no interest, maturity nine months from issuance, convertible at a 35% discount to market after a business combination
Total contemplated financing: $1,400,000, with $1,250,000 still subject to a convertible note purchase agreement yet to be negotiated
Addendum dated March 9, 2026 contemplates $400,000 in aggregate funding disbursed on or prior to March 30, 2026
GalaxyEdge Acquisition Corporation, a blank check company, said its underwriters exercised their over-allotment option in full, buying 1,500,000 additional units at $10.00 for $15 million, with the closing completed on March 12, 2026. Including the March 5, 2026 IPO, total units sold rose to 11,500,000, and the filing states $115,000,000 was placed in a trust account. The filing is administrative and does not describe a business combination target.
Underwriters exercised the over-allotment option in full on March 10, 2026, buying 1,500,000 additional units at $10.00 per unit for $15,000,000 in gross proceeds.
The over-allotment closed on March 12, 2026, bringing total units sold to 11,500,000.
Sponsor Equinox Capital Solutions Limited bought 7,500 private placement units at $10.00 each, for $75,000 in gross proceeds.
The filing states a total of $115,000,000 was placed in a trust account with Continental Stock Transfer & Trust as trustee.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.